Cargando…

Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors

BACKGROUND: Pucotenlimab is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) with a S228P hinge mutation and an engineered Fc domain. Preclinical data suggests that pucotenlimab exerts antitumor effects. In this phase I study, which was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Rujiao, Li, Wenhua, Meng, Yanchun, Gao, Shuiping, Zhang, Jian, Hu, Xichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182631/ https://www.ncbi.nlm.nih.gov/pubmed/34158838 http://dx.doi.org/10.1177/17588359211020528

Ejemplares similares

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
por: Cui, Chuanliang, et al.
Publicado: (2023)

Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
por: Zhang, Jian, et al.
Publicado: (2023)

HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
por: Zhang, Jibin, et al.
Publicado: (2020)

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)

Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
por: Xu, Jianming, et al.
Publicado: (2020)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Breaking the HxNy outbreak
por: Manikandan, Jayapal, et al.
Publicado: (2010)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
por: Wei, Xiao‐Li, et al.
Publicado: (2020)

MON-LB008 PD-L1 Expression in Normal Endocrine Tissues
por: Pollack, Rena, et al.
Publicado: (2019)

Thermal Properties of Bayfol(®) HX200 Photopolymer
por: Blanche, Pierre-Alexandre, et al.
Publicado: (2020)

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
por: Chiu, Joanne W., et al.
Publicado: (2015)

The Chemistry and Physics of Bayfol(®) HX Film Holographic Photopolymer
por: Bruder, Friedrich-Karl, et al.
Publicado: (2017)

Hadron calorimeter of ATLAS 008
por: Chernykh, S, et al.
Publicado: (1994)

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
por: Ke, Hang, et al.
Publicado: (2023)

Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
por: An, Qing, et al.
Publicado: (2019)

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
por: Wang, Jin, et al.
Publicado: (2019)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Efficacy and Safety of the Medium Cut-Off Elisio HX Dialyzer
por: Maduell, Francisco, et al.
Publicado: (2023)

Electrochemical Oxidative Clean Halogenation Using HX/NaX with Hydrogen Evolution
por: Yuan, Yong, et al.
Publicado: (2019)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer
por: Chen, Xue-Hui, et al.
Publicado: (2013)

Comparison of apoA-I helical structure and stability in discoidal and spherical HDL particles by HX and mass spectrometry
por: Chetty, Palaniappan Sevugan, et al.
Publicado: (2013)

The nature of inter- and intramolecular interactions in F(2)OXe(…)HX (X= F, Cl, Br, I) complexes
por: Makarewicz, Emilia, et al.
Publicado: (2016)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
por: Haense, N., et al.
Publicado: (2016)

008 se va con la murga
por: Campoamor, María José
Publicado: (1986)

AB008. Management of fertility post cancer
por: Smith, James
Publicado: (2016)

AB008. Treatment of retroperitoneoscopic adrenalectomy for pheochromocytoma
por: Li, Zeliang
Publicado: (2017)

cmFPA008, an anti-mouse CSF-1R antibody, combines with multiple immunotherapies to reduce tumor growth in nonclinical models
por: Bellovin, David, et al.
Publicado: (2015)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Analysis of relative displacement between the HX wearable robotic exoskeleton and the user’s hand
por: Cempini, Marco, et al.
Publicado: (2014)

Basic features of Ne*–HX (X = Cl, Br) chemi-ionization reactions
por: Falcinelli, Stefano, et al.
Publicado: (2022)

Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer—The CONKO-008 Phase I Investigation
por: Striefler, Jana K., et al.
Publicado: (2022)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
por: Day, Daphne, et al.
Publicado: (2023)

Ultrafast signatures of magnetic inhomogeneity in Pd(1−)(x)Fe(x) (x ≤ 0.08) epitaxial thin films
por: Petrov, Andrey V, et al.
Publicado: (2022)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
por: Powderly, John, et al.
Publicado: (2020)

Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
por: Kojima, Takashi, et al.
Publicado: (2018)

First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors
por: Zheng, Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h21og6if8h8gm58tnasm7b7p5h